Regulatory News has published 1 story about MRI2CT on 8 October 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 8 October 2026.
This page is generated from Regulatory News’ editorial coverage of MRI2CT. It is not an advertisement.
On the record
- Company
- MRI2CT, Inc. (private)
- Headquarters
- Claymont, Delaware (incorporation); research team based in Jerusalem, Israel
- Founded
- Not publicly disclosed
- Regulator
- U.S. Food and Drug Administration (CDRH)
- Latest milestone
- FDA 510(k) clearance, NextMR Spine
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
